Karachaliou Andromachi, Conlan Andrew J K, Preziosi Marie-Pierre, Trotter Caroline L
Disease Dynamics Unit, Department of Veterinary Medicine, University of Cambridge, United Kingdom.
Meningitis Vaccine Project, PATH, Ferney-Voltaire, France Meningitis Vaccine Project, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S594-600. doi: 10.1093/cid/civ508.
The introduction of MenAfriVac in campaigns targeting people aged 1-29 years across the African meningitis belt has successfully reduced meningitis incidence and carriage due to Neisseria meningitidis group A (MenA). It is important to consider how best to sustain population protection in the long term.
We created a mathematical model of MenA transmission and disease to investigate the potential impact of a range of immunization strategies. The model is age structured; includes classes of susceptible, carrier, ill, and immune people (who may be vaccinated or unvaccinated); and incorporates seasonal transmission and a stochastic forcing term that models between year variation in rates of transmission. Model parameters were primarily derived from African sources. The model can describe the typical annual incidence of meningitis in the prevaccine era, with irregular epidemics of varying size. Parameter and structural uncertainty were explored in sensitivity analyses.
Following MenAfriVac introduction at high uptake, the model predicts excellent short-term disease control. With no subsequent immunization, strong resurgences in disease incidence were predicted after approximately 15 years (assuming 10 years' average vaccine protection). Routine immunization at 9 months of age resulted in lower average annual incidence than regular mass campaigns of 1- to 4-year-olds, provided coverage was above approximately 60%. The strategy with the lowest overall average annual incidence and longest time to resurgence was achieved using a combination strategy of introduction into the Expanded Programme on Immunization at 9 months, 5 years after the initial mass campaigns, with a catch-up targeting unvaccinated 1- to 4-year-olds.
These results can be used to inform policy recommendations for long-term vaccination strategies with MenAfriVac.
在非洲脑膜炎带针对1至29岁人群开展的A群脑膜炎球菌结合疫苗(MenAfriVac)接种活动已成功降低了由A群脑膜炎奈瑟菌(MenA)引起的脑膜炎发病率和带菌率。考虑如何长期维持人群保护效果至关重要。
我们创建了一个MenA传播和疾病的数学模型,以研究一系列免疫策略的潜在影响。该模型按年龄分层;包括易感、带菌、患病和免疫人群(可能接种过疫苗或未接种过疫苗)类别;并纳入季节性传播以及一个模拟年际传播率变化的随机强迫项。模型参数主要来源于非洲数据。该模型可以描述疫苗接种前时代脑膜炎的典型年发病率,以及大小不一的不规则流行情况。在敏感性分析中探讨了参数和结构的不确定性。
在高接种率引入MenAfriVac后,模型预测短期内疾病控制效果良好。若后续不再进行免疫接种,预计约15年后疾病发病率会大幅回升(假设疫苗平均保护期为10年)。9月龄时进行常规免疫接种导致的年均发病率低于针对1至4岁儿童的定期大规模接种活动,前提是覆盖率高于约60%。总体年均发病率最低且回升时间最长的策略是采用一种联合策略,即在9月龄时引入扩大免疫规划,在首次大规模接种活动5年后进行,同时针对未接种疫苗的1至4岁儿童进行补种。
这些结果可用于为MenAfriVac的长期疫苗接种策略提供政策建议。